Science Advances publishes proteomics technology from Oblique Therapeutics AB with a potential to bring several novel antibody medicines to large patient populations in multiple disease areas
Science Advances publicerar artikel om proteomikteknik från Oblique Therapeutics AB som kan bidra till utveckling av nya antikroppsläkemedel till stora patientpopulationer inom flera sjukdomsområden
Oblique Therapeutics AB raises 98 MSEK in a private placement investment round
Oblique Therapeutics together with collaborators at Sahlgrenska University Hospital and Karolinska Institutet has been granted 5MSEK by Vinnova.
Oblique Therapeutics and Targovax enter collaboration to target mutant RAS cancers by combining their ONCOS and Abiprot™ platforms
Göteborgsbaserade Oblique Therapeutics AB har gjort potentiellt viktiga upptäckter för antikroppsutveckling mot Covid
Oblique Therapeutics AB has identified a potentially important epitope for generation of SARS-CoV-2 antibodies
Oblique Therapeutics will be presenting at the Inaugural RAS- Targeted Drug Discovery Europe Summit in Vienna in February 2020
Oblique Therapeutics has been recognized as one of the 15 most promising Biotech startups in Europe 2019, by StartUp City magazine
Science Translational Medicine publishes research results from Oblique Therapeutics and Karolinska Institute on a new treatment
Oblique Therapeutics present tumor growth inhibition and Treglowering data for OT1096 congress ESMO
